PRICE HISTORY.
Use the left and right arrow keys to inspect dated observations. Home selects the first observation and End selects the latest.
Key numbers
Published fundamentals and the date each figure was recorded.
API Holdings Limited operates a technology-enabled healthcare platform through its PharmEasy marketplace and group businesses rather than as a single-channel pharmacy. The annual report describes product sales on the PharmEasy marketplace, technology-powered distribution to chemists and institutions through Retailio 1P, and hospital distribution through Aknamed. Retailio 1P procures pharmaceuticals, OTC products, surgical goods and consumables from pharmaceutical companies, then supplies local chemists and institutional customers directly or through Retailio technology. The group's diagnostics activity uses Thyrocare laboratories and offers tests through collection centres, home collection and online booking; PharmEasy Labs is its marketplace-facing diagnostics brand. Other services include fulfilment for pharmaceutical and OTC products sold on the marketplace and technology or software services for doctors and pharmacies. Retailio's app and web platform connect wholesalers and pharmacies for procurement. The disclosed model therefore combines marketplace commerce, B2B distribution, institutional supply, diagnostics and healthcare software and fulfilment services.
About this company
PharmEasy is the consumer-facing brand operated under API Holdings Limited, one of India's largest digital healthcare and e-pharmacy platforms. The business connects patients, pharmacies, diagnostic labs, and hospitals through a single technology layer, allowing users to order prescription and over-the-counter medicines, book diagnostic tests, schedule teleconsultations, and access health products for home delivery. Over time the group expanded from a pure online pharmacy into a broader healthcare ecosystem spanning retail distribution, business-to-business pharmaceutical supply, diagnostics, and software tools for clinics and pharmacies. The company scaled rapidly through both organic growth and acquisitions, most notably the buyout of the diagnostics chain Thyrocare, which added a large pathology and laboratory network to the platform. Its operations cover thousands of pin codes across India, supported by a network of fulfilment centres, partner pharmacies, and logistics infrastructure. This multi-segment model positions API Holdings as a vertically integrated player addressing several parts of the healthcare value chain rather than a single product line. API Holdings has been backed by a roster of prominent venture capital and private equity investors and was, at its peak, valued among India's most highly funded healthcare startups. The company filed draft IPO papers with the market regulator but subsequently withdrew them, choosing instead to strengthen its balance sheet through rights issues aimed at reducing debt and funding continued operations. As a result, its equity shares remain unlisted and are quoted on private secondary markets at an indicative level. PharmEasy draws interest in the unlisted segment because of its brand recognition, its scale across pharmacy and diagnostics, and its status as a closely watched company whose eventual listing intentions remain a subject of market attention. The indicative price reflects negotiated transactions between buyers and sellers in the unlisted space and can move with funding rounds, financial disclosures, and broader sentiment toward digital healthcare. The figures shown here are indicative market data points for information only and do not constitute any form of advice.
COMPANY REGISTRY · ON FILE
THE CREW · BOARD & MANAGEMENT
COMMON QUESTIONS.
Is PharmEasy listed on the stock exchange?+
No. As of 2 September 2026, PharmEasy is an unlisted company whose shares trade over-the-counter; it would list only if and when it completes an IPO.
What is the PharmEasy unlisted share price?+
As of 2 September 2026, the indicative unlisted share price of PharmEasy is ₹6.25 per share. This is an over-the-counter reference price, not a stock-exchange quote.
What indicative minimum amount is displayed for PharmEasy unlisted shares?+
The displayed unit count is 1,600 share(s); at the indicative price of about ₹6.25, the displayed amount is approximately ₹10,000. This is a display convention, not evidence of inventory, an order minimum or a quote.
What is the ISIN of PharmEasy?+
The recorded ISIN of PharmEasy is INE0DJ201029. An ISIN is a 12-character security identifier. Verify it against the issuer and the relevant depository record before using it for any transfer or documentation.
Is trading in PharmEasy unlisted shares legal in India?+
Unlisted shares can be transferred off-market in India, but the legal, tax and compliance position depends on the security, parties, documents and current rules. Verify the intermediary, issuer restrictions and applicable requirements before proceeding.
Is there a lock-in period for unlisted shares?+
A post-listing lock-in may apply under the rules in force at the time. The period and any exemptions can depend on the holder and acquisition, so check the current regulation and the issuer's offer documents rather than relying on a generic period.
Do you guarantee returns?+
No. Unlisted shares carry higher risk and lower liquidity than listed shares. Returns depend on company performance, market conditions and future listing outcomes. This is information only, not investment advice.